National Pharmaceutical Council (NPC) Press Releases - EIN Presswire

Published on August 6, 2026 - 14:16 GMT

New in Health Affairs Forefront: 'Myths of Mandatory International Reference Pricing for Prescription Drugs'

A new article from the National Pharmaceutical Council includes evidence to dispel common myths about mandatory international reference pricing. WASHINGTON, DC, UNITED STATES, August 6, 2026 /⁨EINPresswire.com⁩/ -- A new Health Affairs Forefront article …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on July 22, 2026 - 16:30 GMT

Study Finds Medicare Part D Plans Likelier Than Commercial Plans to Restrict Drug Coverage in Competitive Drug Classes

Analysis of 2024-2026 formulary data found broader declines in coverage across competitive drug classes in Medicare Part D following implementation of the IRA WASHINGTON D.C., DC, UNITED STATES, July 22, 2026 /⁨EINPresswire.com⁩/ -- New research from the …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on July 8, 2026 - 11:00 GMT

New Study Ties Increased Community Pharmacy Access to Lower Racial and Ethnic Disparities in Medication Use

Research underscores the importance of preserving pharmacy access & introduces a “disparity index” tool to measure pharmaceutical inequity. WASHINGTON, DC, UNITED STATES, July 8, 2026 /⁨EINPresswire.com⁩/ -- A new study published in Health Affairs …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on June 22, 2026 - 14:03 GMT

New Research Finds 340B Program Tied to Increased Hospital Assets and Administrative Salaries

Long-term 340B participation is linked to stronger financial assets, with much of the program’s recent growth flowing through child sites at wealthier hospitals WASHINGTON, DC, UNITED STATES, June 22, 2026 /⁨EINPresswire.com⁩/ -- New research published in …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on May 14, 2026 - 15:54 GMT

New Research Identifies Steps to Improve Gene Therapy Contracting and Patient Access

A new NPC study in JMCP proposes consensus-based guidance to support sustainable payment approaches and improve equitable patient access to gene therapies. WASHINGTON, DC, UNITED STATES, May 14, 2026 /⁨EINPresswire.com⁩/ -- New research from the National …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on March 2, 2026 - 17:39 GMT

New Research Explores Gaps in Health Plan Implementation of FDA Label Revisions

Evidence suggests commercial health plans are more likely to delay specialty drug coverage decisions in response to FDA label expansions vs contractions. WASHINGTON, DC, UNITED STATES, March 2, 2026 /⁨EINPresswire.com⁩/ -- New research published in Health …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on December 11, 2025 - 15:37 GMT

New Research Explores Future of Gene Therapy Financing in the U.S.

Research explores landscape of innovative contracts for gene therapies & identifies key barriers & opportunities for future contract development/implementation. WASHINGTON, DC, UNITED STATES, December 11, 2025 /⁨EINPresswire.com⁩/ -- New research …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on October 27, 2025 - 14:00 GMT

CMS Should Not Minimize Unmet Need in IRA’s Medicare DPNP

A new study from NPC & CU finds crucial elements of unmet medical need unaccounted for in current FDA guidelines which inform the IRA’s Medicare DPNP. WASHINGTON, DC, UNITED STATES, October 27, 2025 /⁨EINPresswire.com⁩/ -- Leaders at the Centers for …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on October 16, 2025 - 15:05 GMT

New NPC Analysis Illustrates How IRA’s Medicare Drug Price Negotiation Program May Reshape Pharmaceutical R&D Incentives

Study signals IRA’s widespread potential effects for long-term innovation incentives across disease states & disproportionate impact on small molecule drugs. WASHINGTON, DC, UNITED STATES, October 16, 2025 /⁨EINPresswire.com⁩/ -- A new analysis from …

Distribution channels: Healthcare & Pharmaceuticals Industry, Insurance Industry ...

Published on September 9, 2025 - 14:00 GMT

77% of Investors Say IRA's 'Pill Penalty' Disincentivizes Small Molecule Investments

Early signals of the IRA’s impact on pharmaceutical investor strategy include reduced investment in small molecules and favoring larger launch indications. WASHINGTON, DC, UNITED STATES, September 9, 2025 /⁨EINPresswire.com⁩/ -- Investors across a range …

Distribution channels: Healthcare & Pharmaceuticals Industry, Insurance Industry ...

Published on September 8, 2025 - 14:00 GMT

Study Links 340B Expansion With Higher ACA Premiums

Findings suggest an unintended consequence of 340B expansion is an association with ACA benchmark premium increases estimated at over $2 billion per year. WASHINGTON, DC, UNITED STATES, September 8, 2025 /⁨EINPresswire.com⁩/ -- The 340B Drug Pricing …

Distribution channels: Healthcare & Pharmaceuticals Industry, Insurance Industry ...

Published on September 3, 2025 - 13:30 GMT

Research Finds Post-Approval Cancer Trials Fell After IRA Passage, With Disproportionate Impact on Small Molecule Drugs

Findings highlight concerns of government price regulation and the IRA's "pill penalty." WASHINGTON, DC, UNITED STATES, September 3, 2025 /⁨EINPresswire.com⁩/ -- New research published in Health Affairs Scholar finds that the passage of the …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on August 8, 2025 - 18:37 GMT

New Study Reveals Significant Racial and Ethnic Disparities in Prescription Drug Utilization and Spending Across the US

Research highlights the need for local and condition-specific efforts to achieve equal access to medicine WASHINGTON, D.C., DC, UNITED STATES, August 8, 2025 /⁨EINPresswire.com⁩/ -- Significant racial and ethnic disparities exist in prescription drug …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on July 8, 2025 - 13:50 GMT

Study Shows Critical Misalignment Between Health Plan Utilization Management & Clinical Guidelines for Specialty Drugs

Data from NPC and CEVR reveal utilization management is common even when clinical guidelines do not support its use. WASHINGTON, DC, UNITED STATES, July 8, 2025 /⁨EINPresswire.com⁩/ -- New research by the National Pharmaceutical Council (NPC) and the …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...

Published on June 3, 2025 - 13:34 GMT

What the Growth of Utilization Management Says About the Future of Policy and Patient Access

A new Health Affairs Forefront primer examines the evolution of utilization management and its impact on patient access and policymaking for prescription drugs. WASHINGTON, DC, UNITED STATES, June 3, 2025 /⁨EINPresswire.com⁩/ -- More than 35 years ago, a …

Distribution channels: Healthcare & Pharmaceuticals Industry, Human Rights ...

Published on May 13, 2025 - 14:05 GMT

New Studies Recommend Inclusion of Dynamic Inputs in Cost-Effectiveness Analyses to Better Reflect Drug Value Over Time

Cost-effectiveness models that exclude dynamic pricing likely underestimate a treatment’s benefits versus its costs to society WASHINGTON, DC, UNITED STATES, May 13, 2025 /⁨EINPresswire.com⁩/ -- Two new studies published in Value in Health underscore the …

Distribution channels: Healthcare & Pharmaceuticals Industry, Insurance Industry ...

Published on April 22, 2025 - 17:58 GMT

Observational Research Reveals Unintended Consequences of the Inflation Reduction Act on Post-Approval Clinical Trials

NPC study supports that the IRA reduced evidence generation while raising concerns around the “pill penalty” — impacting innovation and patient access. WASHINGTON, DC, UNITED STATES, April 22, 2025 /⁨EINPresswire.com⁩/ -- New evidence published in …

Distribution channels: Healthcare & Pharmaceuticals Industry, Insurance Industry ...

Published on March 31, 2025 - 15:00 GMT

Study Finds Higher 340B Profit Margins for Facilities Serving Wealthier Communities, With Stronger Bargaining Positions

The findings of a study published in INQUIRY add to the growing body of literature on the 340B program’s unchecked expansion into more affluent communities. WASHINGTON, DC, UNITED STATES, March 31, 2025 /⁨EINPresswire.com⁩/ -- Hospitals and covered …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on March 24, 2025 - 16:04 GMT

Whittington, Garrison, and Campbell: Challenges With Judging and Interpreting a Drug’s Launch Price (AJMC Commentary)

A new publication suggests that decision makers take both a product lifetime view and a broader societal perspective when judging and rewarding value creation. WASHINGTON, DC, UNITED STATES, March 24, 2025 /⁨EINPresswire.com⁩/ -- Drug prices at launch …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on March 20, 2025 - 12:20 GMT

What you need to know about copay accumulators and maximizers

New research in Health Affairs Forefront examines the rise of these cost-shifting programs, the impact on patients, and the policy environment surrounding them. WASHINGTON D.C., DC, UNITED STATES, March 20, 2025 /⁨EINPresswire.com⁩/ -- Well over 50 …

Distribution channels: Business & Economy, Companies ...